Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Journavx is a prescription sodium channel blocker containing suzetrigine. It is indicated for moderate to severe acute pain, including postoperative pain, in adults. Each tablet contains 50 mg of suzetrigine.
read more about journavx ...Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel found in peripheral sensory neurons. Blocking this channel reduces transmission of pain signals from peripheral nerves toward the spinal cord and brain.
Journavx is used in adults with moderate to severe acute pain. Treatment is used for the shortest duration consistent with the clinical goal, and current labeling states that use beyond 14 days has not been studied.
The starting dose is 100 mg by mouth on an empty stomach at least one hour before or two hours after food. Starting 12 hours later, the standard regimen is 50 mg every 12 hours with or without food. Tablets are swallowed whole, and grapefruit is avoided during treatment.
Strong CYP3A inhibitors are contraindicated, and moderate CYP3A inhibitors require dose reduction. Strong or moderate CYP3A inducers are avoided. Severe liver impairment is another reason to avoid treatment, and moderate liver impairment requires a lower dose. The most common adverse reactions in trials were itching, muscle spasms, increased creatine phosphokinase, and rash.
Journavx treats moderate to severe acute pain in adults.
The starting dose is 100 mg taken on an empty stomach.
Starting 12 hours later, the standard regimen uses 50 mg every 12 hours.
No. Current labeling directs patients to avoid food or drink containing grapefruit during treatment.
Drug Trials Snapshots: JOURNAVX. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-journavx. Date Accessed October 6, 2026.
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain. Date Accessed October 6, 2026.
JOURNAVX (Suzetrigine) Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0976da4-1d20-4517-945c-b60ed2f41c12. Date Accessed October 6, 2026.
Suzetrigine: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a625039.html. Date Accessed October 6, 2026.
Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. https://pubmed.ncbi.nlm.nih.gov/40117446/. Date Accessed October 6, 2026.